Rgenta Therapeutics

Recent Finacing

Series A

Recent Raise

$52M

Rgenta Therapeutics develops oral small-molecule RNA-targeting medicines for oncology and neurological disorders using a genomics-driven platform that identifies RNA processing targets and designs spliceosome-modulating small-molecule glues.

Founded 2018

Massachusetts, United States

11-50

Private

rgentatx.com

Highlights

Focus Areas

Biotechnology

Health Care

Medical

Oncology

Pharmaceutical

Therapeutics

Recent Investors

A

Financials

$90M

Total Raised

3

Funding rounds

8

Investors

Team

Upgrade to view the team

See the team members at Rgenta Therapeutics.